Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CuraGen, Topotarget deal

CRGN received exclusive ex-European development and commercialization rights to TopoTarget’s PXD101, a histone deacetylase (HDAC) inhibitor in Phase

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE